Nuclear Medicine Market
Nuclear Medicine Market - Global Industry Assessment & Forecast
Segments Covered
- By Type Diagnostic Nuclear Medicine, Therapeutic Nuclear Medicine, Brachytherapy Isotopes
- By Applications Diagnostic Applications, Procedural Volume Assessment, Diagnostic Procedures, Therapeutic Procedures
- By Procedural Volume Assessment Diagnostic Procedures, Therapeutic Procedures
- By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
Base Year: | 2022 |
Forecast Years: | 2023 - 2030 |
Historical Years: | 2017 - 2021 |
Revenue 2022: | USD 7.88 Billion |
Revenue 2030: | USD 20.37 Billion |
Revenue CAGR (2023 - 2030): | 12.60% |
Fastest Growing Region (2023 - 2030) | Asia Pacific |
Largest Region (2022): | North America |
Customization Offered
- Cross-segment Market Size and Analysis for Mentioned Segments
- Additional Company Profiles (Upto 5 With No Cost)
- Additional Countries (Apart From Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request Customization Speak To Analyst
Sr. No. | Offering | Report Coverage |
1. | Market Size | In terms of Revenue (USD Million) |
2. | Historic Data | 2017 to 2021 |
3. | Forecast Data | 2023 to 2030 |
4. | Market Drivers, Restraints, Opportunities, & Regional Market Trends | Yes |
5. | Market Attractiveness Analysis | Yes |
6. | Segment Analysis | Maximum Segments |
7. | Regional Coverage | 5 Regions |
8. | Country Coverage | Top 22 Countries |
9. | Competitive Landscape and Company Market Share Analysis | Yes. Exhaustive information will be provided in two separate chapters of Competitive Landscape and Company Profiles. |
10. | Porter’s Five Forces Analysis | Yes. |
11. | Value Chain Analysis | Yes |
12. | PEST Analysis | Yes |
13. | Regulatory Landscape | Yes |
14. | Technology Landscape | Yes |
15. | COVID-19 Impact Analysis | Yes. Exhaustive information for Key Strategies Undertaken by Companies, Impact Assessment of the COVID-19 Pandemic by Region, along with Short-term and Long-term dynamics. |
16. | Top startups to watch out for | Yes |
17. | Top 3 Trends to Watch | Yes |
18. | Top 3 Strategies Followed by Major Players | Yes |
19. | Top 3 Predictions by Vantage Market Research | Yes |
20. | Discussion Guide | Yes |
21. | Key Primary Respondents - VERBATIM | Yes |
22. | Transcripts from the Primary Respondents | Additional Cost USD 1,000 |
23. | Others/Miscellaneous |
FAQ
Frequently Asked Question
What is the global demand for Nuclear Medicine in terms of revenue?
-
The global Nuclear Medicine valued at USD 7.88 Billion in 2022 and is expected to reach USD 20.37 Billion in 2030 growing at a CAGR of 12.60%.
Which are the prominent players in the market?
-
The prominent players in the market are Curium, Bracco Imaging S.P.A., Pharmalogic, EczacibaÅŸi-Monrol Nuclear Products, Cardinal Health, NTP Radioisotopes SOC LTD. (A Subsidiary of South African Nuclear Energy Corporation), GE Healthcare, Nordion Inc. (A Sotera Health Company), Advanced Accelerator Applications (AAA) (A part of Novartis), Northstar Medical Radioisotopes LLC, Eckert & Ziegler, Joint Stock Company Isotope (JSC Isotope), Bayer AG, Siemens Healthineers, Jubilant Draximage Inc. (A Subsidiary of Jubilant Pharma), Lantheus Medical Imaging Inc., Global Medical Solutions, Shine Medical Technologies, Isotopia Molecular Imaging Ltd., Sinotau Pharmaceutical Group, Institute of Isotopes Co. Ltd., China Isotope & Radiation Corporation, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Cyclopharm, IRE Elit.
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 12.60% between 2023 and 2030.
What are the driving factors fueling the growth of the market.
-
The driving factors of the Nuclear Medicine include
- Increasing incidence and prevalence of target conditions
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the Nuclear Medicine in 2022.